SLC25A1 activation in skeletal muscle to enhance insulin sensitivity

Overview

This research explores a novel therapeutic strategy for improving insulin sensitivity by activating the SLC25A1 gene in skeletal muscle. Skeletal muscle is responsible for up to 90% of an animal's glucose utilization, and loss of metabolic flexibility in this tissue is closely linked to impaired glucose uptake and insulin resistance. Prior work has shown that SLC25A1 enhances glucose use and oxidative capacity in other cell types, positioning it as a promising target for addressing diabetes and related metabolic disorders at the muscle level.

Technical specifications

Key features:

• Programmable epigenetic activation using dCas9-P300CORE targeted histone acetylation to increase SLC25A1 expression
• In vitro validation using differentiated canine skeletal muscle myotubes transfected with SLC25A1-targeting gRNA ribonucleoprotein complexes
• Metabolite flux analysis to assess glucose oxidation and oxidative capacity changes
• Evaluation of metabolic adaptations to determine therapeutic efficacy for diabetes intervention
• Focus on restoring skeletal muscle metabolic flexibility to improve global glucose handling

Technology readiness level

This research is at an early validation stage, with proposed in vitro studies to establish proof-of-concept for SLC25A1 activation in skeletal muscle. The work seeks partnership support for procurement of supplies and funding for key personnel to conduct the proposed experiments. Future directions include extending findings to assess whole-body insulin sensitivity outcomes.